Home » Stocks » Antares Pharma

Antares Pharma, Inc. (ATRS)

Stock Price: $2.97 USD 0.06 (2.06%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.98 +0.01 (0.34%) Oct 23, 7:47 PM

Stock Price Chart

Key Info

Market Cap 493.30M
Revenue (ttm) 137.61M
Net Income (ttm) 5.56M
Shares Out 166.09M
EPS (ttm) 0.03
PE Ratio 99.00
Forward PE 10.40
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.97
Previous Close $2.91
Change ($) 0.06
Change (%) 2.06%
Day's Open 2.92
Day's Range 2.89 - 2.98
Day's Volume 639,015
52-Week Range 1.60 - 5.13

More Stats

Market Cap 493.30M
Enterprise Value 488.61M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 166.09M
Float 152.61M
EPS (basic) 0.04
EPS (diluted) 0.03
FCF / Share 0.05
Dividend n/a
Dividend Yield n/a
Earnings Yield 1.01%
FCF Yield 1.75%
Payout Ratio n/a
Shares Short 4.17M
Short Ratio 5.05
Short % of Float 2.74%
Beta 1.23
PE Ratio 99.00
Forward PE 10.40
P/FCF Ratio 57.11
PS Ratio 3.58
PB Ratio 8.43
Revenue 137.61M
Operating Income 9.23M
Net Income 5.56M
Free Cash Flow 8.64M
Net Cash 4.69M
Net Cash / Share 0.03
Gross Margin 53.33%
Operating Margin 6.71%
Profit Margin 4.00%
FCF Margin 6.28%
ROA 4.57%
ROE 11.24%
ROIC 9.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$6.25*
(110.44% upside)
Low
4.50
Current: $2.97
High
8.00
Target: 6.25
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12463.5554.5252.2245.6626.5020.6222.5816.4612.82
Revenue Growth94.9%16.58%4.39%14.38%72.28%28.53%-8.67%37.17%28.39%-
Gross Profit73.3932.4927.0523.4126.2015.2611.4213.069.668.55
Operating Income0.99-4.10-15.59-24.12-20.46-35.11-20.85-11.45-4.44-6.03
Net Income-2.03-6.52-16.74-24.34-20.66-35.15-20.51-11.43-4.39-6.09
Shares Outstanding16315715615514713112711096.9983.17
Earnings Per Share-0.01-0.04-0.11-0.16-0.14-0.27-0.16-0.10-0.05-0.07
Operating Cash Flow-10.62-17.32-23.09-15.20-28.20-26.33-14.97-10.47-1.93-6.08
Capital Expenditures2.656.650.73-4.88-5.64-4.66-2.74-3.26-0.32-0.06
Free Cash Flow-7.97-10.68-22.36-20.08-33.84-31.00-17.71-13.73-2.25-6.14
Cash & Equivalents45.7227.8931.5627.7247.9140.0363.0873.2131.379.85
Total Debt47.0925.1324.86-------
Net Cash / Debt-1.362.776.7027.7247.9140.0363.0873.2131.379.85
Assets13388.2874.3466.3384.5668.7788.9395.5341.9615.14
Liabilities78.2549.2840.7921.1117.5227.5818.228.9810.828.51
Book Value54.5039.0033.5545.2267.0441.2070.7186.5531.146.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Antares Pharma, Inc.
Country United States
Employees 178
CEO Robert F. Apple

Stock Information

Ticker Symbol ATRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: ATRS
IPO Date October 2, 1996

Description

Antares Pharma focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.